<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04615663</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/19/0354</org_study_id>
    <nct_id>NCT04615663</nct_id>
  </id_info>
  <brief_title>Assessment of Burden Disease in Patients With Mast Cell Disorders</brief_title>
  <acronym>MCD&amp;BuDi</acronym>
  <official_title>Assessment of Personal, Psychosocial, Work, and Economic Burden in Patients With Mast Cell Disorders,</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The symptoms caused by mast cell disorders can have a significant impact on the state of&#xD;
      health of individuals, constituting a real burden for them, and consequently altering their&#xD;
      quality of life. It therefore seems important to clarify the impact on the quality of life,&#xD;
      on the psycho-affective sphere, on professional life and on the direct and indirect costs&#xD;
      caused by the disease, as well as on the &quot;patient's remaining burden&quot;. It seems possible by a&#xD;
      longitudinal study (patient follow-up over 1 year).&#xD;
&#xD;
      Primary objective is Assessment of quality of life in adult patient with mast cell diseases&#xD;
      at M0.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mast cell activation symptoms are due to the release of mast cell mediators after&#xD;
      uncontrolled activation of mast cells. The release by mast cells of mast cell mediators&#xD;
      (tryptase, histamine, prostaglandins, serotonin) results in mast cell activation symptoms,&#xD;
      found in mast cell activation syndrome but also in mastocytosis. These symptoms interested&#xD;
      the skin, gastrointestinal gut, pulmonary, cardiovascular and neuropsychiatric organs, etc.&#xD;
&#xD;
      In mastocytosis, along with these symptoms of mast cell activation, the infiltration of&#xD;
      different organs by abnormal mast cells produces many clinical signs related to the excess of&#xD;
      monoclonal mast cells present in the organs.&#xD;
&#xD;
      According to our clinical experience, the impact of mast cell disorder on various dimensions&#xD;
      of life, including economic life, seems important, but it has never accurately evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 28, 2020</start_date>
  <completion_date type="Anticipated">September 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 28, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of life of mast cell disorder patients</measure>
    <time_frame>Baseline</time_frame>
    <description>Quality of life is evaluated with the WHOQOL-bref questionary. This validated questionnaire in French assesses six dimensions of quality of life.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mast cell disorder patient's life quality</measure>
    <time_frame>6 months</time_frame>
    <description>Quality of life is evaluated with the WHOQOL-bref.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mast cell disorder patient's quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>Quality of life is evaluated with the WHOQOL-bref.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Mastocytosis</condition>
  <condition>Cutaneous</condition>
  <arm_group>
    <arm_group_label>face-to-face patients</arm_group_label>
    <description>During this visit, the investigator will complete the SMI score.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Email patients</arm_group_label>
    <description>this visit at M0 + 7d will correspond to the emailing of the Mc_QoL and Burden_MCD questionnaires completed by the patient.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Score SMI</intervention_name>
    <description>the investigator will complete the SMI score</description>
    <arm_group_label>face-to-face patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Prospective, descriptive study, both transversal and longitudinal, open, monocentric,&#xD;
        performed in 200 patients with mast cell disease and follow-up at the CEREMAST Toulouse&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patient (&gt; 18 years old) with confirmed mast cell disorder according to&#xD;
             international criteria&#xD;
&#xD;
          -  Patient affiliated to social security regime&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient under legal protection (guardianship, curators or court order)&#xD;
&#xD;
          -  Patient does not speak French&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>65 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LIVIDEANU Cristina, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>LIVIDEANU Cristina, MD</last_name>
    <phone>0567778135</phone>
    <phone_ext>+33</phone_ext>
    <email>livideanu.c@chu-toulouse.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>NEGRETTO Mathilde</last_name>
    <phone>05 67 77 81 68</phone>
    <phone_ext>+33</phone_ext>
    <email>negretto.m@chu-toulouse.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cristina BULAI LIVIDEANU</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina BULAI LIVIDEANU, MD</last_name>
      <phone>567778135</phone>
      <phone_ext>+33</phone_ext>
      <email>livideanu.c@chut-oulouse.fr</email>
    </contact>
    <contact_backup>
      <last_name>Isabelle OLIVIER, PhD</last_name>
      <phone>0561777051</phone>
      <phone_ext>+33</phone_ext>
      <email>olivier.i@chut-oulouse.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>June 16, 2020</study_first_submitted>
  <study_first_submitted_qc>November 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2020</study_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Burden</keyword>
  <keyword>quality of life</keyword>
  <keyword>mast cell disease</keyword>
  <keyword>work impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mastocytosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

